CANCER ANSWER: (41 OF 352)
Liver metastases convert to a resectable status more readily than lung metastases following systemic chemotherapy in your patients with metastatic CRC. True or False?
Answer Explanation:
True. In a recent study, patients with unresectable, metastatic CRC were treated with oxaliplatin- or irinotecan-based first-line systemic chemotherapy. While 24% of patients with liver metastases converted to a resectable status, only 7% of patients with lung metastases converted.
Nozawa H, et al. Oncology. 2017;92(3):135-141.
CANCER ANSWER: (42 OF 352)
Weight gain following CRC treatment is associated with decreased survival in your patients. True or False?
Answer Explanation:
False. In a recent study, weight loss following CRC treatment was associated with worse cancer-specific and overall mortality. However, weight gain did not correlate with cancer-specific or overall mortality in these patients.
Meyerhardt JA, et al. Cancer Epidemiol Biomarkers Prev. 2017;26(1):30-37.
CANCER ANSWER: (43 OF 352)
Which variable is a significant risk factor associated with perforation following endoscopic submucosal dissection for colorectal tumors?
Answer Explanation:
Submucosal fibrosis. Both variables were significantly associated with perforation in a recent study; multivariate analysis showed that fibrosis was a significant risk factor. Endoscopic closure allows effective nonsurgical management in cases of intraprocedural perforation during endoscopic submucosal dissection.
Takamaru H, et al. Gastrointest Endosc. 2016;84(3):494-502.
CANCER ANSWER: (44 OF 352)
Which is NOT a germline mutation associated with Lynch syndrome in your patients with gastric cancer?
Answer Explanation:
CDH1. Currently, germline mutations in EPCAM, MLH1, MSH2, MSH6, and PMS2 are associated with gastric cancer development in Lynch syndrome patients. CDH1 is the causative mutation for hereditary diffuse gastric cancer.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Gastric Cancer Version 3.2016. © National Comprehensive Center Network, Inc. 2017, All rights reserved.
CANCER ANSWER: (45 OF 352)
Which risk factor for gastric cancer is an autosomal recessive disease?
Answer Explanation:
Ataxia-telangiectasia. Autosomal recessive genetic disorders which can lead to gastric cancer development include ataxia-telangiectasia, Bloom syndrome, and xeroderma pigmentosum. Bloom syndrome and hereditary breast and ovarian cancer syndrome are autosomal dominant disorders.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Gastric Cancer Version 3.2016. © National Comprehensive Center Network, Inc. 2017, All rights reserved.
CANCER ANSWER: (46 OF 352)
Which is NOT a micronutrient which currently requires follow-up monitoring in your patients who received surgical resection for gastric cancer?
Answer Explanation:
Calcium. According to current guidelines, patients treated for gastric cancer should receive a complete history and physical examination every 3-6 months for 1-2 years, then every 6-12 months for 3-5 years. Furthermore, gastric resection patients should be monitored for vitamin B12 and iron deficiency.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Gastric Cancer Version 3.2016. © National Comprehensive Center Network, Inc. 2017, All rights reserved.
CANCER ANSWER: (47 OF 352)
What is the current guideline recommendation for adequate surgical margins during complete resection in your patients with gastric cancer?
Answer Explanation:
4 cm or greater. Surgery is the primary treatment for early stage gastric cancer; complete resection with 4 cm or greater margins is considered optimal. However, the optimal type of resection and extent of lymph node dissection required is currently debated.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Gastric Cancer Version 3.2016. © National Comprehensive Center Network, Inc. 2017, All rights reserved.